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Abstract 
The purpose of this QI project was to improve provider adherence to the Institute for Clinical 
Systems Improvement (ICSI) Guidelines for Adult Depression in Primary Care to enhance the 
screening, diagnosis, treatment, and management of adult major depressive disorder (MDD). 
MDD is a widespread, disabling, and treatable psychiatric disorder that is primarily treated and 
managed by primary care providers (PCPs). Untreated depression is prone to become chronic 
and can lead to pain, suffering, disability, increased morbidity and mortality, and premature 
death, with serious repercussions for the individual and society. Universal and routine screening 
in primary care for depression in adults, in combination with adequate systems of support, is 
recommended by ICSI guidelines and has been found to be a cornerstone in the management of 
MDD. Despite this, depression remains underrecognized, underdiagnosed, and undertreated in 
primary care. The project objectives aimed at aligning the clinic with ICSI’s guidelines to 
increase screening for depression, routine assessment for the severity of symptoms, referrals to 
behavioral health specialists (BHS), and minimize suicide risk. An MDD protocol was developed 
and all adult patients were universally and routinely screened for depression using PHQ-2 and/or 
PHQ-9 over an 8-week period. Project interventions were successful at initiating change toward 
improving provider adherence to ICSI guidelines. Screening rates for depression, routine 
assessment rate for the severity of symptoms, provider adherence rate to the suicide protocol, and 
the referral rate to a BHS increased from pre-intervention to post-intervention. 
Keywords: Major depressive disorder, MDD, primary care, adult depression, depression 
screening, PHQ-9  
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Impact of Depression 
 Major depression is a common and treatable psychiatric disorder that affects over 300 
million individuals globally and roughly 9% of the U.S. population (Maurer, Raymond, & Davis, 
2018; World Health Organization [WHO], 2018). This disabling disorder is associated with 
astronomical medical costs and is linked to diminished role functioning and quality of life and 
increased morbidity and mortality; it is also linked with major co-morbidities such as arthritis, 
cardiovascular disease, asthma, cancer, diabetes, hypertension, and chronic respiratory and pain 
conditions (Institute for Clinical Systems Improvement [ICSI], 2016; Kessler & Bromet, 2013). 
If left untreated, major depression can lead to extensive pain, suffering, disability, increased 
morbidity and mortality, and even death (ICSI, 2016; Maurer et al., 2018).  
Approximately 13 to 16% of adults in the United States will endure symptoms of 
depression in their lifetime, and nearly 4 to 8% of adults suffer from major depression in a given 
year (American Psychiatric Association [APA], 2017). A majority of Americans with depression 
seek care and treatment in primary care setting, with PCPs prescribing 79% of antidepressant 
medications and providing care for nearly 60% of patients with depression (Barkil-Oteo, 2013; 
ICSI, 2016; Maurer et al., 2018). Yet PCPs fail to recognize major depression in up to one half of 
their patients with depression (APA, 2017; ICSI, 2016; Maurer et al., 2018). Consequently, less 
than one half of adult patients experiencing major depression actually receive treatment, with 
only 20 to 40% of those being treated showing significant improvement over a 12-month period 
(ICSI, 2016). Routine screening for depression in adults 18 years of age and over is 
recommended by the ICSI guidelines for adult depression in primary care and the U.S. 
Preventive Services Task Force (USPSTF) in combination with adequate systems of care in 
place, and is cornerstone for the recognition, diagnosis, treatment, and management of 
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depression (ICSI, 2016; Maurer et al., 2018). Despite the USPSTF’s recommendation, screening 
rates for depression remain low in primary care, with less than 5% of adults being screened 
(APA, 2017a). With depression being underdetected, underdiagnosed, and undertreated in 
primary care, there is a crucial need for PCPs to be adequately skilled in the recognition, 
diagnosis, treatment, and management of major depression (ICSI, 201; Maurer et al., 2018). 
PCPs are instrumental for the improvement of the recognition, diagnosis, and treatment of major 
depressive disorder (MDD), and without adequate screening and adherence to evidence-based 
guidelines for depression the patient, their loved ones, and society will continue to suffer from 
the deleterious effects of this burdensome disorder (Cameron, Habert, Anand, & Furtado, 2014; 
ICSI, 2016; Maurer et al., 2018).  
Statement of the Problem  
Major depression is a common, disabling, and treatable psychiatric disorder that affects 
over 300 million people globally and 9% of Americans (WHO, 2018; Maurer et al., 2018). 
According to WHO (2018), depression is a leading cause of disability and is projected to become 
the second leading cause of disability globally by 2020 (Kessler & Bromet, 2013). This 
psychiatric disorder is associated with astronomical societal costs and greater functional 
impairment than many other chronic diseases, including arthritis and diabetes (Centers for 
Disease Control and Prevention [CDC], 2018). Rates of depression differ based on age, sex, 
income, and health behaviors (CDC, 2018).  
Despite depression being a treatable disorder and the majority of patients with depression 
receiving care from PCPs, depression is typically underrecognized, underdiagnosed, and 
undertreated in the primary care setting (Cameron et al., 2014; Maurer, 2012;). In most cases, 
even with recognition and treatment, outcomes are less than optimal, with greater than 75% of 
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depressed patients in the United States experiencing recurrence (Maurer, 2012). Untreated 
depression is likely to become a chronic disease and experiencing just one episode of depression 
places an individual at a 50% greater risk for experiencing another episode, only further 
increasing the chances of recurrence (APA, 2013). Untreated depression can lead to pain, 
suffering, increased morbidity and mortality, and even death from suicide, with serious 
repercussions for the individual, their family, and society (Maurer et al., 2018). Depression is 
underrecognized, underdiagnosed, and undertreated in primary care, highlighting the need for 
universal routine screening for adults per the USPSTF recommendations and adherence to 
evidence-based guidelines by PCPs, such as the ICSI (2016) guidelines for adult depression in 
primary care, to enhance the diagnosis, treatment, and management of MDD (APA, 2010; ICSI, 
2016; Maurer et al., 2018).  
Background and Significance 
Depression is a widespread mental health disorder that is on the rise and affects nearly 
300 million people of all ages globally (WHO, 2018). Major depression is one of the most 
common mental disorders in the United States and, according to the 2016 National Survey on 
Drug Use and Health study, approximately 16.2 million American adults suffer from depression, 
which roughly equates to 6.7% of the adult population (National Institute of Mental Health 
[NIMH], 2017). The 12-month prevalence of MDD in the United States is nearly 7%, with 
females experiencing 1.5 to 3-fold higher rates (8.5%) compared to males (4.8%) (APA, 2013; 
NIMH, 2017). Incidence of depression globally is 3% (Jesulola, Micalos, & Baguley, 2018). 
Depression is one of the leading causes of injury and disability worldwide and is 
associated with higher rates of chronic disease, significant health care needs and utilization, 
impaired functioning, increased mortality from suicide, premature death, and overall higher 
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morbidity and mortality (CDC, 2018; Kessler & Bromet, 2013; WHO, 2018). Individuals with 
major depression have an overall increased risk of mortality 1.4 times greater than that of the 
general population and are more prone to premature death than the general population as a result 
of untreated mental or physical health issues (Funk, Drew, & Knapp, 2012). Mental health is 
crucial to an individual’s wellbeing, to strong family and interpersonal relationships, and to live a 
full and valuable life (Office of Disease Prevention and Health Promotion, 2018). Mental health 
and physical health are indistinguishably connected and it is well established throughout the 
literature that depression is significantly correlated with the risk, occurrence, management, 
progression, and outcomes of severe chronic diseases and conditions such as diabetes, stroke, 
hypertension, asthma, arthritis, cancer, cardiovascular disease, arthritis, and a multitude of 
chronic pain conditions and mental health disorders that account for higher mortality rates and 
premature death in comparison with the general population (Kessler & Bromet, 2013; Office of 
Disease Prevention and Health Promotion, 2018). Individuals with depression often have 
comorbid conditions, and undiagnosed or untreated depression can lead to worsened outcomes in 
cardiovascular disease, cancer, and other conditions (ICSI, 2016).  
The burden of depression has an impact on the depressed individuals, but can also 
adversely affect their families, society, and the health care system as a whole (CDC, 2016). The 
direct financial impact or economic burden is pretty straightforward and measures health care 
expenditures, which were estimated to be $210.5 billion dollars in 2010 for depression, and 
included workplace costs, direct costs, and suicide-related costs (Greenberg, Fournier, Sisitsky, 
Pike, & Kessler, 2015). The indirect financial impact is all other costs related to depression, 
which is not as straightforward as the direct financial impact. Depression is costly on the 
individual level in many ways, as it tends to be associated with higher risk of morbidity and 
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mortality, premature death particularly related to suicide, functional impairment, low education 
level, marital disruption, reduced role functioning, elevated risk of comorbidities, low income, 
low work performance, and unemployment, which only compound the financial burden 
(Scrandis & Watt, 2013). The burden of depression nationally and globally is astronomical, as 
higher costs are associated with increased health care needs (Maurer, 2012). Although there are 
known efficacious treatments available for depression, fewer than half of the individuals affected 
receive adequate treatment, which is linked to higher health care costs and poor health outcomes 
(Maurer, 2012; WHO, 2018). Another issue contributing to the global burden and rising costs 
associated with depression is the misdiagnosis or mismanagement of the disease (WHO, 2018).  
Depression can be recurrent or persistent, and substantially impairs cognitive, social, 
physical, and overall functioning (Jesulola et al., 2018). The underlying cause of depression is 
complex with a number of factors being implicated in the pathogenesis (Jesulola et al., 2018). 
Despite continued research efforts in the understanding of the pathogenesis of depression, the 
precise mechanisms in which depression develops is unknown which is partly due to depression 
being a complex and heterogenous disorder with numerous potential etiologies (Jesulola et al., 
2018). A number of factors alone and in combination, such as genetics, biogenic amine 
deficiency, environmental, immunologic, endocrine, and neurogenesis, have been identified in 
the literature as playing a role in the pathophysiology of depression (Jesulola et al., 2018). 
Evidence supports the role of particular neurotransmitters such as the 5HT serotonin receptors, 
Norepinephrine (NE), and Dopamine (DA) in the development and clinical manifestation of 
depression and is aligned with the monoamine hypothesis that proposes that reduced availability 
of these monoamine neurotransmitters results in decreased neurotransmission and neurocognitive 
function, which may consequently lead to depression (Jesulola et al., 2018). Although evidence 
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suggests that genetics plays a role in the development of depression, only a small number of 
genetic polymorphisms have significant relationships with MDD, and include the APOE, GND3, 
MTFHR 6771T, SLC6A3, SLC6A4, and the DRD4 genes (Jesulola et al., 2018). Hormonal and 
endocrine dysfunction, Hypothalamus-Pituitary-Adrenal axis dysfunction, and a number of 
immunological or inflammatory cytokines have also been correlated to the pathogenesis of 
depression (Jesulola et al., 2018).  
The Diagnostic and Statistical Manual of Mental Disorders, 5
th
 ed. (DSM-5) classifies 
mental health/psychiatric disorders, includes diagnostic criteria for depression, and per ICSI 
guidelines, should be utilized by the PCP to establish the diagnosis of depression (APA, 2013; 
ICSI, 2016). Classic symptoms of depression include a depressed mood, loss of interest in 
activities, difficulties with concentration, feelings of guilt, sadness, or worthlessness, and suicidal 
ideation (APA, 2013; ICSI, 2016; Kessler & Bromet, 2013). Per the DSM-5, depressive 
disorders include MDD, persistent depressive disorder (dysthymia), premenstrual dysphoric 
disorder, disruptive mood dysregulation disorder, substance/medication induced depressive 
disorder, depressive disorder due to another medical condition, other specified depressive 
disorder, and unspecified depressive disorders, with two of the most common forms consisting of 
MDD and persistent depressive disorder (APA, 2013; NIMH, 2016). The common feature of all 
of these depressive disorders is the presence of a sad, depressed, irritable mood accompanied by 
cognitive and somatic disturbances that affect the individual’s functional capacity; the duration, 
timing, and presumed etiology are what differs among the disorders (APA, 2013).  
MDD represents the classic condition within the depressive disorders and requires five or 
more of the following symptoms: depressed mood (most of the day), marked loss of 
interest/pleasure in activities, significant and unintentional weight loss/gain or changes in 
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appetite, insomnia/hypersomnia, psychomotor agitation/retardation, fatigue/loss of energy, 
feelings of worthlessness/excessive or inappropriate guilt, decreased ability to think or 
concentrate/indecisiveness, recurrent thoughts of death/suicidal ideation/suicide attempt. Per the 
DSM-5 diagnostic criteria, these must be present nearly every day, with the exception of weight 
change and suicidal ideation, and must be present during the same 2-week period and represent a 
clear-cut change from previous functioning (APA, 2013). At least one of the symptoms must be 
either depressed mood or loss of interest or pleasure in order for the diagnosis to be established 
(APA, 2013; ICSI, 2016). MDD diagnostic criteria requires the episode to be of at least two 
weeks’ duration, with symptoms that cause clinically significant distress or impairment in social, 
occupational, or other areas of functioning that cannot be attributable to a substance or medical 
condition (APA, 2013; ICSI, 2016). In addition, the episode must not be better explained by 
schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other 
schizophrenia spectrum/psychotic disorders (APA, 2013). Finally, the patient should never have 
had a manic or hypomanic episode, although this exclusion does not apply if the mania or 
hypomania was substance or medically induced (APA, 2013; ICSI 2016).  
Current evidence-based treatment of MDD includes a pharmacologic approach alone or 
in combination with non-pharmacological approaches such as cognitive behavioral therapy 
(CBT) or psychotherapy, and/or Electroconvulsive Therapy (ECT), depending on the symptoms 
and severity as recommended in the ICSI 2016 guidelines (APA, 2010; ICSI, 2016; Maurer, 
2012). Selection of the initial treatment approach should consider clinical features such as the 
severity of symptoms, the presence of co-occurring conditions, and other factors such as prior 
treatment history or responses and patient preferences (Anderson, 2011; APA, 2010; ICSI, 
2016). Pharmacologic evidence-based treatment with first-line antidepressants such as Selective 
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Serotonin Reuptake Inhibitors, Serotonin Norepinephrine Reuptake Inhibitors, Norepinephrine 
Dopamine Re-uptake Inhibitors, or mirtazapine are recommended for a period of at least six 
months per the ICSI 2016 guidelines, with assessment of efficacy at four weeks to be determined 
by a 50% reduction in symptoms and tolerance of side effects, which can be measured using the 
Patient Health Questionnaire-9 (PHQ-9)  (Anderson, 2011; APA, 2010; ICSI; 2016; Maurer, 
2012). Re-evaluation of efficacy should be performed at six, eight and 12 weeks and if there is 
not a 50% reduction in symptoms by eight weeks, the antidepressant should be substituted for 
another first-line antidepressant (Anderson, 2011; APA, 2010; Maurer, 2012). Maintenance with 
first-line antidepressant should continue at an optimal and tolerated dose for at least six months 
(Anderson, 2011; APA, 2010; Maurer, 2012).  
The overall treatment goals for depression aim to achieve remission of the depressive 
episode (i.e., PSQ-9 score of less than 5), resolution of depressive symptoms, a return to the 
patient’s baseline level of functioning, and a prevention of future relapse (APA, 2010; Anderson, 
2011; Cameron et al., 2014; ICSI, 2016). The PHQ-9 assessment should be used routinely for 
subsequent visits by PCPs as a management tool to monitor the severity and treatment outcomes 
of depression (ICSI, 2016). This measurement-based approach to depression care, with 
consideration of PHQ-9 results and side effect evaluation in combination with evidence-based 
treatment algorithms, can help guide the PCP in the treatment of depression and toward 
remission for the patient (ICSI, 2016; Siu et al., 2016). The PHQ-9 assessment is also a valid 
tool to assess the risk for or presence of suicide ideation and can be used by the PCP to help 
determine if urgent referral to crisis specialty care is needed (ICSI, 2016; Siu et al., 2016).  
 Adequate screening, assessment, diagnosis, and treatment is needed to reduce the 
incidence, prevalence, and recurrence of depression as well as the chronicity of the disease, and 
PCPs are instrumental in reducing the burden of depression and improving the quality of care.
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With fewer than half of all individuals who experience depression seeking treatment, PCPs 
should promote awareness, adequately screen, and help to reduce the stigma surrounding mental 
health, in an effort to overcome barriers to access to care (ICSI, 2016; Mauer 2012; WHO; 
2017). Despite the availability of various efficacious treatments for depression, the risk of 
relapse remains extremely high with recurrences, severity, and treatment resistance ever-
increasing (Gilli, Vicens, Roca, Anderson, & McMillan (2015). Considering these issues, PCPs 
should work at developing interventions geared toward preventing relapse or recurrence of 
depression and for overall prevention, as these are major concerns regarding the long-term 
management and care of patients with depression (Gilli et al., 2015). Routine screening for 
depression and adherence to the ICSI (2016) health care guidelines for adult depression in 
primary care can help guide PCPs in achieving improved recognition, diagnosis, and treatment 
of MDD in the primary care setting. 
Assessment 
An independent family medicine practice located in an urban city of South-Central Texas 
was the site for implementation of an evidence-based quality improvement project aimed at 
aligning the clinic with the ICSI 2016 guidelines for adult depression in primary care for the 
screening, diagnosis, treatment, and management of patients with MDD. The staff involved in 
the project at the clinic included the providers (one physician, three physician assistants), four 
receptionists, three medical assistants, one licensed vocational nurse, one referral coordinator, 
and an office manager. 
The clinic sees an average of 600 patients per week. Roughly 1% of patients are 12 to 17 
years of age, 17% are 18 to 24 years of age, 26% are 25 to 44 years of age, 34% are 45 to 64 
years of age, and 22% are 65 years of age and over. Patients’ ethnic/racial backgrounds are 
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60.4% Hispanic, 56.2% White Non-Hispanic, 1.4% Black, 1.3% Asian, and 0.7% classified as 
“other.” The male to female ratio is estimated at 50:50. A majority of the patients speak Spanish 
or English, with the greatest preference typically being Spanish. All of the clinic’s staff are 
bilingual and speak both English and Spanish, with the exception of one staff member. 
Demographics of the patients served at the clinic are comparable to those of the county in which 
it is located (Health Collaborative 2016; U.S. Census Bureau, 2016). Approximately 27% of 
patients seen within the clinic over 6 months (June 2018-December 2018) sought psychiatric 
services or care, with 21% of those patients having a diagnosis of MDD.  
A community health needs assessment for the county in which the clinic is located 
identified depression as being one of the community’s top priorities and the most common 
mental health issue requiring complex solutions and interventions (Health Collaborative, 2016). 
This predominately Hispanic community has low income and poverty rates that are higher than 
average in comparison to national rates, as well as low educational levels and health literacy, 
which contributes to the community’s increased risk for depression (Health Collaborative, 2016). 
Key barriers to care identified for those with mental illness within this community were a lack of 
involvement and awareness of behavioral health issues by PCPs, a low number of referrals to 
behavioral health specialists by PCPs, a heavy reliance on medications by PCPs for mental 
health issues when other interventions may be necessary or potentially more effective, and a lack 
of collaboration with or connection by PCPs to behavioral health resources within the 
community (Health Collaborative, 2016). According to the National Alliance on Mental Illness, 
Hispanics are less likely to utilize behavioral health specialty services, further highlighting the 
need for improvements in care at this clinic for patients with depression (Health Collaborative, 
2016). With the clinic’s patient population and surrounding community being predominately 
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Hispanic, having multiple health disparities, and at an increased risk for depression, there is a 
critical need to enhance the management of depression at this clinic.  
An October 2018 microsystem assessment was performed, and indicated that the clinic 
and the providers lacked the uniform use of evidence-based guidelines for the screening, 
diagnosis, treatment, and management of MDD. Various guidelines were being utilized by the 
providers when providing care for depressed patients, with diagnosis being based primarily on 
the DSM-IV diagnostic criteria for depression. Screening of patients for depression was not 
being conducted in the clinic and clear evidence-based protocols were lacking regarding the 
treatment, referral, and follow-up for patients with MDD. A protocol was also lacking for the 
management of patients with depression expressing suicidal ideation and/or those posing an 
imminent threat to the safety of themselves or others. The providers lacked a uniform approach 
regarding this issue and indicated that the patient was typically advised to seek care at a local 
emergency department and if the patient refused, a relative of the patient was notified to help 
convince the patient to seek emergency care. However, if the patient refused to seek emergent 
care as advised, it was uniformly expressed by the providers that they could not intervene any 
further unless the patient was actively harming themselves or someone else in the clinic. This 
established a need for provider education and a protocol to address this safety concern.  
The clinic’s referral resources for mental health specialists were very limited and 
outdated. The ICSI guidelines call for the universal and routine screening for depression in adult 
patients, use of the DSM-5 for the diagnosis of MDD, and an adequate system of care in place 
and aligned with evidence-based guidelines to ensure accurate diagnosis, effective treatment, and 
appropriate follow-up for the management of MDD. The clinic lacked uniform use of evidence-
based guidelines for the screening, diagnosis, treatment, and management of patients with MDD. 
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Readiness for Change 
Results of the October 2018 microsystem assessment and the ICSI guidelines were 
discussed and reviewed with key stakeholders and it was established that the clinic was not 
aligned with the ICSI’s 2016 guidelines for adult depression in primary care. Prior to being 
apprised of the ICSI guidelines, the providers had been unaware of the recommendation for 
universal and routine screening of adult patients for depression and the clinical utility of PHQ-9 
for the screening, monitoring of severity and treatment outcomes, and management of 
depression. Successive review of the guidelines indicated that a protocol needed to be developed 
to align the clinic with the ICSI guidelines. The providers in the clinic were motivated to 
improve the quality of care for depression in the clinic and were very receptive to the project. All 
staff and providers in the clinic expressed enthusiasm and a desire to participate in the project 
and the implementation of the evidence-based ICSI guidelines for adult depression in primary 
care in the clinic as a way to improve the quality of care. 
Project Identification  
Purpose and Objectives 
The purpose of this evidence-based quality improvement project was to improve 
adherence of the clinic’s PCPs to the ICSI's 2016 health care guideline for adult depression in 
primary care, and consequently improve the quality of care provided for adult patients with 
major depressive disorder. The ICSI guidelines call for routine screening for depression in adults 
aged 18 and older, with adequate systems of care in place, and can be used by PCPs to support 
the effective diagnosis, treatment, and management of major depression in the primary care 
setting. 
 The objectives of this evidence-based quality-improvement project were to: 
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1. Increase screening for depression for adult patients from the pre-intervention rate of 
0% to 90% in 8 weeks, using Patient Health Questionnaire-2 (PHQ-2) and PHQ-9.  
2. Increase the percentage of adult patients with an established diagnosis of depression 
who are routinely assessed for severity of symptoms from the pre-intervention rate of 
0% to 50% in 8 weeks, using PHQ-9.  
3. Increase provider adherence rate to the MDD Suicide Protocol from the pre-
intervention rate of 0% to 100% in in 8 weeks for patients who scored positive to 
question 9 of PHQ-9.  
4. Increase the percentage of referrals for adult patients with depression to mental health 
specialists as appropriate, per the ICSI 2016 guidelines for adult depression in 
primary care, from the pre-intervention rate of 0% to 50% by the completion of the 
eighth week of project implementation.  
Anticipated Outcomes 
By meeting these objectives, there will be an increase in the recognition of depression in 
adult patients, in the assessment of the presence and severity of depressive symptoms, in 
provider adherence to the MDD suicide protocol, and in referrals for adult patients with major 
depression to behavioral health specialists as appropriate, per evidence-based guidelines. The 
clinic will align with the USPSTF’s recommendation for universal routine screening for 
depression in adults and will be in compliance with the ICSI’s 2016 guidelines for adult 
depression in primary care.  
Summary and Strength of Evidence  
Depression is a widespread, debilitating, and treatable psychiatric illness most commonly 
managed and treated within the primary care setting (ICSI, 2016). A majority of patients in the 
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United States with depression are being seen and treated in the primary care setting and, despite 
effective treatment being available, outcomes remain suboptimal in primary care. Extensive 
literature supports the assertion that depression is underdetected, underdiagnosed, and 
undertreated by PCPs (ICSI, 2016; Siu, 2016; WHO, 2018). Screening is key in the prevention of 
depression, as effective recognition, diagnosis, and treatment is linked with lower chronicity, 
morbidity and mortality, recurrence, and incidence (CDC, 2017; Maurer, 2012; Maurer et al., 
2018; Scrandis & Watt, 2013). The USPSTF found substantial evidence that screening improves 
the accurate identification of depression in adult patients in primary care settings, yet screening 
rates for depression continue to remain astoundingly low in primary care (ICSI, 2016; Siu et al., 
2016).  
The ICSI guidelines and the USPSTF recommend routine universal screening for 
depression in all adults, 18 years of age and over, at least annually when accompanied by 
systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up 
(ICSI, 2016; Maurer et al., 2018; Scrandis & Watt, 2013). Although screening for depression in 
adults in primary care is supported within the literature as being beneficial with adequate systems 
of care in place, evidence fails to distinguish the optimal timing and intervals for screening or 
what actually comprises adequate systems of care (ICSI, 2016; Siu et al., 2016).  
Screening for depression is commonly done with validated tools such as PHQ-2 and 
PHQ-9, which are cornerstones in supporting the diagnosis of depression and for monitoring 
progress with treatment (ICSI, 2016; Maurer et al., 2018; Siu et al., 2016). The PHQ-2 
assessment is a brief, valid, and reliable two-question screening tool that can be used for initial 
intake and routine screening for depression (ICSI, 2016;   et al., 2016; Siu et al., 2016). One of 
the most efficacious screening tools used in primary care is PHQ-9, which has been validated to 
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detect depression and monitor the presence and severity of depressive symptoms (ICSI, 2016; 
Scrandis & Watt, 2013). If a patient screens with a positive PHQ-2 result, PHQ-9 screening tool 
can be administered and is supported in the literature as being an effective tool in the primary 
care setting to confirm the diagnosis, assess the severity of symptoms and suicidality, and 
monitor response to treatment for depression (ICSI, 2013; Maurer et al, 2018; Mitchell, 
Yadegarfar, Gil, & Stubbs, 2016; Siu et al., 2016). The PHQ-9 assessment is identified 
extensively throughout the literature as being an effective management tool for depression and 
can be used routinely for follow-up visits to monitor the severity and treatment of outcomes 
(ICSI, 2016; Mitchell et al., 2016; Siu et al., 2016). The clinical utility of PHQ-9 for the 
management of depression in primary care is extensively supported in the literature, as it can be 
used by PCPs to help guide and modify treatment plans (ICSI, 2013; Maurer et al., 2018; 
Mitchell et al., 2016; Siu et al., 2016). PHQ-9 results and side effect evaluation, combined with 
evidence-based treatment algorithms, can help PCPs to push patients with depression toward 
remission (ICSI, 2013; Maurer et al., 2018; Mitchell et al., 2016; Siu et al., 2016). 
A multitude of studies suggest that screening for depression in clinical practice without 
adequate systems of care in place is of minimal benefit (Cameron et al, 2014; ICSI, 2016; 
Maurer, 2012; Mitchell et al., 2016; Siu et al., 2016). Programs implementing depression 
screening in conjunction with adequate support systems are emphasized as being crucial and 
beneficial (Cameron et al, 2014; ICSI, 2016; Maurer, 2012; Mitchell et al., 2016; Siu et al., 
2016). Adequate systems of care are commonly identified in the literature as having sufficient 
clinical staff to ensure that patients are screened and, if the patient screens positive, that 
evidence-based care is being provided to ensure appropriate diagnosis, treatment, referral, and 
follow-up (Cameron et al, 2014; ICSI, 2016; Maurer, 2012; Mitchell et al., 2016; Siu et al., 
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2016). The lowest level of support necessary to implement effective screening for depression 
was supported in the literature as requiring, at a minimum, a staff member to advise PCPs of 
positive screening results, and a protocol that facilitates referral to evidence-based treatment for 
depression (Cameron et al, 2014; ICSI, 2016; Maurer, 2012; Mitchell et al., 2016; Siu et al., 
2016). A meta-analysis of 52 randomized controlled trials compared the effects of treatment with 
antidepressants alone versus combined treatment with antidepressants and psychotherapy for 
adult patients with depression, and results indicated that monotherapy with antidepressants may 
not constitute optimal treatment for depression and that combined treatment to include 
antidepressants and psychotherapy is more effective than antidepressant medication alone for the 
treatment of depression (Cuijpers et al., 2014). A multidisciplinary team-based approach that 
encompasses self-management support and care coordination is widely supported in the literature 
as being effective for the management of depression in primary care (Cameron et al, 2014; ICSI, 
2016; Maurer, 2012; Siu et al., 2016). Recent studies have found that approximately 25 to 60% 
of individuals contemplating suicide seek attention for a medical problem from a PCP in the 
weeks prior to death and typically do not seek psychiatric help, which highlights the need for 
adequate systems to be in place in primary care settings to help identify and monitor patients at 
risk for suicide (SAMHSA-HRSA, 2019). A multitude of literature supports the recommendation 
of screening patients for suicidal ideation using a standardized screening tool such as PHQ-9 
(Ingelse, 2016). The PHQ-9 assessment can be used to identify individuals at risk for suicide and 
has been found to be more reliable than clinical judgement or assessment alone (ICSI, 2016; 
Ingelse, 2016; SPRC, 2017). Further research is needed to identify, assess, and address barriers 
in establishing adequate systems of care (ICSI, 2016; Mitchell et al., 2016; Siu et al., 2016).  
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Methods 
Project Intervention 
Prior to project implementation, screening for depression or suicide ideation with a 
validated instrument was not being conducted by PCPs within the clinic. Referrals to a 
behavioral health specialist for patients with a diagnosis of MDD were very infrequent and were 
not based on evidence-based guidelines for depression. Overall, the clinic lacked uniform use of 
evidence-based guidelines by PCPs for screening, diagnosis, treatment, and management of 
patients with MDD. Routine screening for adults 18 years of age or older for depression in the 
primary care setting using PHQ-2 and PHQ-9 has been shown to improve detection, diagnosis, 
and outcomes of depression (ICSI, 2016). PHQ-2 is a valid assessment instrument for detecting 
depression and has been established to be up to 97% sensitive and 67% specific in adults 
(Maurer, 2012). The PHQ-2 assessment scores range from 0 to 6, with a cut point of ≥ 3, which 
suggests clinically significant that should prompt further screening and assessment with PHQ-9 
(ICSI, 2016). PHQ-9 is a valid assessment tool for measuring depression severity, and for 
detecting and monitoring depression in the primary care setting, with a sensitivity of 0.77 and a 
specificity of 0.85 in adults (ICSI, 2016). PHQ-9 can be used by PCPs to help identify 
depression and to guide and monitor treatment. However, these screening tools should only be 
used by PCPs to enhance and not replace the clinical interview (ICSI, 2016). Screening of the 
general adult population with the combination PHQ-2 and PHQ-9 can improve the detection, 
diagnosis, outcomes, and functioning for patients with depression (ICSI, 2016). 
Prior to project implementation, one-on-one interactive education was carried out with 
each PCP on the screening, diagnosing, treatment, referral, and management of MDD and 
included the screening procedure using PHQ-2 and PHQ-9, how to score and interpret PHQ-2 
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and PHQ-9, DSM-5 criteria for diagnosing MDD, how to translate PHQ-9 depression scores into 
practice based on DSM-5 criteria and ICSI guidelines, PHQ-2 and PHQ-9 screening timing and 
interval, how to assess and minimize suicide or homicide risk, when to refer to a behavioral 
health specialist, and how to use PHQ-9 scores to monitor treatment response and severity of 
MDD (see Appendix M). Each PCP in the clinic was provided with a copy of the clinic’s MDD 
Provider Handbook, which included a copy of the ICSI 2016 guidelines, copies of the PHQ-2 
assessment and PHQ-9 assessment with instructions on how to score and interpret the forms, a 
copy of DSM-5 criteria for MDD (see Appendix J), a copy of MDD in primary care (see 
Appendix K), a copy of the clinic’s MDD provider algorithm (See Appendix L), a copy of MDD 
provider treatment recommendation table (see Appendix M), and a copy of the clinic’s MDD 
suicide protocol for the assessment, management, and, minimization of suicide risk (see 
Appendix N). The project implementation plan was discussed through one-on-one interactive 
education sessions provided to all clinic staff regarding their roles and responsibilities during the 
implementation phase of the project. Laminated copies of the MDD provider algorithm and the 
MDD provider treatment recommendation table were posted in each patient room within the 
clinic for provider referral. Laminated copies of the first two pages of the MDD suicide protocol 
were posted for reference on the wall in the provider area, near the referral coordinator’s desk, 
near the office manager’s desk, and on the counter in the front reception area. Data collection 
sheets were color coordinated according to provider in order to track weekly provider adherence 
screening rates.  
Also prior to project implementation, a referral system was initiated and established with 
a nearby psychiatric outpatient clinic. Collaboration between the psychiatrist/owner of the 
psychiatric practice and the medical director/owner of the clinic was fostered in an effort to 
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increase referrals to mental health specialists, as suggested in ICSI guidelines. An online referral 
portal was established by the nearby psychiatric outpatient clinic in the EHR at the project 
site/clinic in which same-day/immediate or routine referrals could easily be made online by the 
PCPs, as needed.  
Beginning on day one of implementation, all adult patients aged 18 years and older being 
seen in the clinic were administered PHQ-2 form in English or Spanish, based on their language 
preference, by the front desk receptionist to screen for depression. Verbal consent from the 
patient to administer PHQ-2 was obtained by a front desk staff member, who filled in the 
applicable section of the data collection forms, which were color coded and selected based on the 
provider seeing the patient. Once the PHQ-2 form was completed, the patient returned the form 
to the front desk receptionist, who then placed it with the patient's face sheet and appropriate data 
collection sheet in a bin for the Licensed Vocational Nurse (LVN) or Medical Assistant (MA) 
responsible for triaging and rooming the patient. The LVN or MA took the completed PHQ-2 
form, data collection form, and the patient’s face sheet with them as they roomed the patient and 
obtained vital signs. The LVN or MA scored the PHQ-2 form and made note on the patient’s 
face sheet and data collection form of the PHQ-2 score and result. The LVN or MA then 
determined whether or not the patient had a previous or existing diagnosis of depression by 
reviewing the face sheet with previous diagnoses listed and by asking the patient. If the patient 
had a current or previous diagnosis of depression, or if they screened positive for depression 
using PHQ-2 with a score of at least three or greater, the LVN or MA administered PHQ-9 to the 
patient in their room to complete while they were waiting to be seen by their PCP.  
The PCP interpreted the PHQ-2 results and then scored and interpreted the results of the 
PHQ-9 test. The PCP used the PHQ-9 assessment to help determine the severity of depressive 
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symptoms and to establish a baseline for patients without a previous diagnosis of depression or 
for the monitoring of treatment response and severity of depressive symptoms for patients with a 
previous diagnosis of MDD. The PCP assessed all patients with a positive PHQ-2 result for 
suicidal ideation using Question 9 of the PHQ-9 and in accordance with the clinic’s MDD 
suicide protocol. The PCP followed the MDD provider algorithm, the provider treatment 
recommendation table, and the clinic’s MDD suicide protocol for the assessment and 
minimization of suicide risk and for the treatment of the patient. The PCP recorded the PHQ-9 
score, whether or not the patient had a positive response for Question 9 of PHQ-9, whether or not 
the patient was assessed for SI, whether or not the patient was positive for SI, and whether or not 
the patient was referred to a mental health specialist, to include the reason the referral was made 
or not made on the data collection form.  
Referral of the patient to a behavioral health specialist, for inpatient evaluation or 
treatment, or for further psychiatric treatment was made by the PCP and based on their clinical 
judgment and the clinic’s MDD provider algorithm, MDD provider treatment recommendation 
table, and the MDD suicide protocol. After seeing the patient, the PCP was responsible for filing 
the data collection sheets in a file folder according to the day of the week.  
The implementation phase was conducted over an eight-week period in which every adult 
patient aged 18 and older was initially screened for depression using PHQ-2. Patients with a 
previous diagnosis of depression or who screened positive for depression using PHQ-2 (score ≥ 
3) were also administered PHQ-9 and screened further for depression to help establish a 
diagnosis and/or baseline of MDD, assess the severity of depressive symptoms, and assess for 
the presence of suicidal ideation. All patients with a previous diagnosis of MDD during the 
eight-week implementation phase were administered PHQ-9 routinely at every visit to monitor 
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treatment response and the severity of depressive symptoms. All patients being seen by a 
provider in the clinic during the first eight weeks of project implementation were included in 
post-intervention data collection and analysis.  
Data Collection sheets were kept in a file folder and stored in a locked drawer in the 
clinic’s provider area. The data collection sheets were reviewed weekly in the clinic and data was 
entered and tracked using an excel spreadsheet. Weekly screening rates were calculated for the 
providers by comparing the daily ledger of their patients to their total number of data collection 
forms for each day. Results for provider adherence were posted weekly in the clinic’s breakroom 
to encourage provider adherence and project participation.  
Organizational Barriers and Facilitators  
Organizational barriers identified included resistance to change by staff; time constraints 
for PCPs and front desk receptionists related to the implementation of screening, which is a fast-
paced and time sensitive environment; and high staff turnover. PCP resistance to referring 
patients with depression to behavioral health specialists was another barrier to the project, and to 
increasing referral rates to behavioral health specialists, as this was viewed by a majority of the 
PCPs as losing revenue. Unforeseen circumstances occurred in which only three providers were 
able to participate for a duration of 6 weeks during project implementation, with only two 
providers participating the entire 8-week duration of project implementation. Lastly, high 
turnover of front desk staff occurred during project implementation, which required 
modifications to be made to the screening process with PHQ-2. Consequently, the LVN or MA, 
instead of the front desk reception staff, were responsible for administering both the PHQ-2 and 
PHQ-9 screening tools while rooming and triaging the patients for the remaining phase of project 
implementation.  
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Potential project facilitators included the clinic staff’s willingness to change and improve 
processes for the diagnosis, treatment, and management of MDD, and increased visits and 
reimbursements for the clinic related to screening with PHQ-2 and PHQ-9. The providers were 
very open to collaborating with behavioral health specialists to improve care for adult 
depression. Collaborations between the owner of the primary care clinic in which the project was 
implemented and with a psychiatrist and owner of a nearby psychiatric outpatient facility was 
fostered and established, which resulted in a system for referral and collaborative care. An 
electronic referral portal was implemented by the office manager of the psychiatric facility into 
the EHR at the clinic, in which providers could schedule same-day or routine psychiatric 
appointments for patients in need of referral. The providers were very satisfied with the user 
friendliness of the referral portal and uniformly expressed that having a psychiatric referral 
source with immediate availability would increase the referral rate to behavioral health 
specialists, because a perceived barrier to patients being referred was the long wait times to be 
seen by a behavioral health specialist.  
Ethical Considerations 
Screening for depression can lead to false positive results and consequent inappropriate 
diagnosis and treatment (Sheehan & McGee, 2013). Literature suggests that screening alone 
cannot be used to establish the diagnosis of depression and is only beneficial with adequate 
systems of care in place to ensure accurate diagnosis, treatment, and follow-up (Siu et al., 2016). 
Screening positive for depression also involves implications for confidentiality and informed 
consent (Sheehan & McGee, 2013). Confidentiality should be maintained at all times and 
consent should be obtained from the patient prior to screening for depression regarding the 
disclosure of information and how it will be used (Sheehan & McGee, 2013). At the clinic, 
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patient confidentiality of positive screening results was maintained at all times and patients were 
made aware of how the screening results would be handled. Verbal consent from the patient was 
obtained by clinical staff prior to administration of PHQ-2 and/or PHQ-9. 
Screening for suicide risk in patients can pose ethical concerns for providers, as the ICSI 
guidelines recommend emergency detention for patients who refuse treatment and are deemed to 
be imminently dangerous to themselves or others (ICSI, 2016). Seeking emergency detention for 
a patient requires the provider to report the threat to local law enforcement and breach patient 
confidentiality (ICSI, 2016). Consequently, the provider may be confronted with an ethical and 
legal dilemma in which the duty to maintain the patient’s confidentiality conflicts with the duty 
to protect the patient’s and public’s health and safety. Currently, there is no national consensus 
on whether a provider has a duty to warn individuals who are not his or her patients who could 
foreseeably be endangered, to protect them, or both (McMullen, Howie, & Philipsen, 2013). 
Although national consensus doesn’t exist regarding the duty to warn, the seminal case (Tarasoff 
v. Regents of the University of California, 1976) set a standard of duty to protect third parties 
against harm and, although only legally binding in California, has had far reaching implications 
and has set legal standards in many states across the nation (Barloon & Hilliard, 2016). In 
accordance with Texas Health and Safety Code §611.004 (2005), Texas is a permissive state and 
the healthcare provider has no duty to inform law enforcement of a threat of violence and is 
granted a permissive duty to warn, with the decision of whether to warn or not to warn being left 
up to the provider (McMullen et al., 2013). Providers should consider the legal, ethical, and 
moral aspects and be familiar with pertinent rules, laws, and regulations to help address the 
dilemma and to avoid any possible legal action (McMullen et al., 2013). 
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Results 
In order to evaluate outcomes for the project, the percent change from pre-intervention to post-
intervention was calculated for each objective after 8 weeks of intervention implementation (see 
Figure 1). The percentage increase calculation can be used to measure the success of the project 
objectives and to determine if goals were met, as the pre-intervention number for each objective 
was zero. The percentage increase calculation can be determined by working out the difference 
between the two numbers (number of patients’ post-intervention minus number of patient’s pre-
intervention), which determines the percentage increase. The percentage increase calculation can 
then be used to determine if screening for depression with PHQ-2 and PHQ-9 for adult patients 
increased, if the percentage of adult patients with depression who were assessed by PCPs for the 
presence and severity of depressive symptoms increased with use of PHQ-9, if the percentage of 
providers adhering to the MDD suicide protocol increased, and if the percentage of referrals for 
adults with depression to a behavioral health specialist increased using the ICSI guidelines for 
(see Table 1). 
Figure 1. Objective outcomes: Percent change from pre-intervention to post-intervention for 
each objective. 
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Objective 1 
The first objective aimed to increase the screening rates for adult depression by 90% 
using PHQ-2 and PHQ-9. During the 8-week project implementation period a total of 2,312 adult 
patients were seen in the clinic and were eligible for initial screening for depression with PHQ-2, 
with 2,242 (97%) of those patients actually being screened (see Figure 2). Of the 2,242 patients, 
670 (30%) screened using PHQ-2 scored positive (PHQ-2 score  3), with 71 out of the 670 
(11%) patients scoring positive already having an existing diagnosis of depression, and 599 out 
of the 670 (89%) patients scoring positive without a previous diagnosis of depression. Of the 
2,242 patients, 86 (4%) screened using PHQ-2 scored negative with an existing diagnosis of  
Table 1 
Demographic Characteristics of Patients  
Characteristics n = 2,312 % 
Gender 
Male 1,087 47% 
Female 1,225 53% 
Race/Ethnicity 
 White (Non-Hispanic) 1,018       44% 
Hispanic 1,225    53% 
African American 23  1% 
Other 46  2% 
Age (in years) 
   18–24 486   21% 
25–44 786 34% 
45–64 647 28% 
IMPROVING PROVIDER ADHERENCE TO MDD GUIDELINES 33 
depression and were also eligible for further screening with PHQ-9. The total number eligible for 
further screening with PHQ-9 were 756 patients. A total of 711 of the 756 eligible patients (94%) 
were actually screened using PHQ-9 (see Figure 3). Of the 711 adult patient, 585 (82%) without  
a previous diagnosis of depression were screened for depression to establish a baseline using 
PHQ-9, while 126 (18%) of adult patients with a previous or existing diagnosis of depression 
were screened further for depression using PHQ-9 to monitor the severity of depressive 
symptoms and treatment response (see Figure 5). Of the 585 patients who scored positive on 
PHQ-2 without an existing diagnosis of depression and who were screened further with PHQ-9, 
205 (35%) scored positive for depression (PHQ-9 score  10) and were newly diagnosed (see 
Figure 4). Total screening rates for all adult patients during project implementation using PHQ-2 
was 97% (see Figure 2), while the total screening rate using PHQ-9 was 94% (see Figure 3). The 
screening rates for depression in adults increased from the pre-intervention rate of 0% to post 
intervention by 97% using PHQ-2 and by 94% using PHQ-9 (see Figure 1).  
Figure 2. Eligible patients screened for depression by PCP using PHQ-2 (n = 2,312). 
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Figure 3. Eligible patients screened for depression by PCP using PHQ-9 (n = 756). 
Figure 4. PHQ-9 Screening results for patients without a previous diagnosis of 
depression (n = 585). 
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Figure 5. PHQ-9 screening results for patients with a previous diagnosis of depression (n = 
126). 
Objective 2 
The second objective aimed to increase the percentage of patients with depression who 
were routinely screened for the severity of symptoms using PHQ-9 by 50% post intervention. A 
total of 157 adult patients with an existing diagnosis of depression were initially screened in the 
clinic during project implementation using PHQ-2 and were eligible for further screening using 
PHQ-9. Of the 157 patients eligible to be screened with PHQ-9, 126 patients (81%) were 
actually screened to assess the severity of depressive symptoms (see Figure 6). Overall, 
screening and assessment in patients with depression by PCPs for the severity of depressive 
symptoms using PHQ-9 increased from a pre-intervention rate of 0% to a post-intervention rate 
of 81% (see Figure 1). 
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Figure 6. Patients with a previous diagnosis of depression that were screened and assessed by 
the PCP using PHQ-9 (n = 126). 
Objective 3 
The third objective aimed to increase provider adherence to the MDD suicide protocol by 
100% for patients responding positively to question 9 of PHQ-9. A total of 711 patients were 
assessed by the PCP for suicidality using Question 9 of PHQ-9. Of the 711 patients, 14 (0.02%) 
who were screened with PHQ-9 had a positive response to question 9 (see Figure 7). The 
providers adhered 100% to the MDD suicide protocol for the 14 patients scoring positive to 
question 9 of PHQ-9, with all 14 patients being further assessed for suicide, referred, and 
followed up appropriately, per the MDD suicide protocol. Of the 14 patients responding positive 
to Question 9 of PHQ-9, only 3 of those patients (21%) were actually deemed to be of high 
suicide risk and were appropriately and immediately referred to a behavioral health specialist 
(see Figure 8).  
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IMPROVING PROVIDER ADHERENCE TO MDD GUIDELINES 37 
Figure 7. Patient responses to Question 9 of PHQ-9 (n = 711). 
Figure 8. Referral types made by the PCP to a behavioral health specialist for 
patients responding positively to Question 9 of PHQ-9 (n = 14). 
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Objective 4 
The fourth objective aimed to increase the referral rate for patients with depression to a 
behavioral health specialist per ICSI guidelines by 50%. A total of 75 out of 288 patients (26%) 
eligible for referral to a behavioral health specialist who either had depression (PHQ-9 score  
10) or were deemed a high suicide risk were referred to a behavioral health specialist. Of the 75
referrals made, 72 (96%) were for routine referral to a behavioral health specialist, while the 
remaining 3 (4%) were made for immediate referral due to high suicide risk (see Figure 9). Of 
the 288 patients, 213 (74%) with depression (PHQ-9 score  10) who were eligible for referral to 
a behavioral health specialist were not referred (see Figure 9). The reasons for non-referral to a 
behavioral health specialist were documented by the providers on the data collection form and 
were categorized as either not being indicated, not being needed as treatment was being provided 
by the PCP, or due to an other unspecified reason, with 41 patients (19%) being documented by 
the providers as “not indicated,” 134 patients (63%) being documented as not being made due to 
“treatment being provided by the PCP,” and the remaining 38 patients (18%) being documented 
as not being referred due to “other” reason (see Figure 10). Although the objective goal was not 
specifically met, the referral rate for patients with depression to a behavioral health specialist 
using the protocols and ICSI guidelines increased by 26% post-intervention, falling short of the 
goal of 50% (see Figure 1).  
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Figure 9. Referral types made by PCP for eligible patients to a behavioral health specialist (n = 
288). 
Discussion 
Although this quality improvement project successfully increased the screening rates for 
depression using PHQ-2 and PHQ-9, the overarching aim was to improve provider adherence to 
ICSI guidelines for the treatment and management of adult depression, to improve the quality of 
care and patient outcomes. The MDD protocols developed for this project were useful at 
initiating change toward improving provider adherence to evidence-based guidelines for adult 
depression. However, additional time and further exploration would be needed beyond the scope 
of this project to fully determine if the quality, efficiency, and effectiveness of care were 
improved for adults with depression and to identify and adequately address any specific areas of 
weakness.  
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Figure 10. Reasons per PCP for non-referral of eligible patients to a behavioral health specialist 
(n = 213). 
The project successfully increased screening rates and the recognition and diagnosis of 
depression for patients being seen in the clinic who may have otherwise gone undetected. 
However, research extensively supports that screening alone does not translate into significant 
improvements in care and patient outcomes (Picardi et al., 2016). Previous studies targeting 
depression screening in primary care settings have demonstrated the significance of having 
adequate resources and systems of care in place to allow for further evaluation, treatment, and 
follow-up, if needed, as screening without support is futile and can create a potential for liability 
(ICSI, 2016; Siu et al., 2016). Evidence also supports a need for collaborative care between PCPs 
and behavioral health specialists, in combination with screening, as being crucial to improving 
treatment adequacy, patient outcomes, and the quality of care for adult patients with depression 
in primary care settings (Cuijpers et al., 2014; ICSI, 2016). Collaborative care and additional 
psychotherapy have been supported extensively in the literature as being more beneficial to 
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patients with depression in comparison with pharmacotherapy alone, with psychotherapy being 
the most strongly linked to long-term prevention of relapse (Ostergaard & Moldrup, 2011).  
Overall, the interventions were successful in improving provider adherence to ICSI 
evidence-based guidelines for the screening, treatment, and management of depression in adults. 
Screening rates for depression using PHQ-2 and PHQ-9, the routine assessment of the severity of 
depressive symptoms in depressed patients using PHQ-9, provider adherence rate to the MDD 
suicide protocol, and the referral rate for adults with depression to a behavioral health specialist 
increased from pre-intervention to post-intervention. The MDD provider handbook and protocols 
developed for the clinic were useful in identifying, treating, and managing care for adult patients 
with depression and for minimizing and managing the risks of suicide. The MDD provider 
handbook was a valuable means to keep the providers informed of how to properly screen, 
diagnose, treat, and manage care for adult patients with depression and for those at risk for 
suicide, and provided adequate tools and resources for protocol completion. The MDD protocol, 
which includes the MDD provider treatment algorithm, the MDD provider treatment 
recommendation table, and the MDD suicide protocol is transferrable to other primary care 
clinics and can be modified as needed to fit the individual needs of the clinic and staff.  
Limitations 
 A major limitation to the project was the time constraint, as the project implantation 
phase could only be conducted for a period of 8 weeks, making it challenging to determine the 
impact the interventions had on improving the quality of care for adults with depression (ICSI, 
2016). The PHQ-9 assessment, in addition to being a valid standardized tool to screen for 
depression, can also be used as measurement-based tool by the provider to quantify baseline 
severity of depressive symptoms and to monitor treatment response. The measurement-based 
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approach using PHQ-9 can help the provider determine the efficacy of treatment by comparing 
the baseline PHQ-9 score to the PHQ-9 score/s performed during subsequent visits (Anderson, 
2011; APA, 2010; Maurer, 2012). A 50% reduction in depressive symptoms, or of the PHQ-9 
score, should be achieved within 8 weeks from the initiation of treatment, with a PHQ-9 score of 
less than 5 indicating remission of the depressive episode (APA, 2010; Anderson, 2011; 
Cameron et al., 2014; ICSI, 2016). PHQ-9 scores can be used by the provider as a measurement-
based approach to ascertain treatment response, remission rates, and recurrence rates and can 
help guide the patient to remission (ICSI, 2016; Siu et al., 2016). However, project 
implementation was limited to 8 weeks and more time would be needed to fully measure 
treatment response, remission rates, and recurrence rates to determine the effectiveness of the 
routine use of the PHQ-9 in improving patient outcomes.  
Although screening with PHQ-2 and PHQ-9 for depression improved the recognition of 
depression and suicide risk in patients, positive screening results for depression and suicide risk 
resulted in increased time and utilization of resources. Time constraints associated with 
screening for depression was a barrier voiced by staff during project implementation, as 
additional time was required by providers to discuss PHQ-2 and PHQ-9 screening results and 
related treatment interventions. Despite this barrier, the clinic’s MDD protocol helped serve as a 
guide for the clinical staff and efficiency of care seemed to improve as they became more 
familiar with the protocol.  
Referrals to behavioral health specialists per ICSI guidelines could not adequately be 
measured by this project, as the measures used (PHQ-9 scores of  10; high suicide risk) did not 
fully capture all ICSI’s guideline recommendations for referral to a behavioral health specialist. 
In addition, the data collection form only captured two specific reasons for non-referral, which 
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included “not indicated” and “treatment being provided by PCP,” and one non-specific reason of 
“other.” The “other” option, which was to be completed by the provider on the data collection 
form, was followed by a blank space, with the intention of having the provider specify the reason 
by filling in the blank. However, providers did not write out the “other” reason and instead 
circled the option, which did not provide insight into other possible reasons for non-referral. 
Further exploration would be needed to determine areas of weakness and in-depth reasons for 
non-referral in order to improve referral rates for depressed patients to behavioral health 
specialists per ICSI guidelines.  
Recommendations  
With the project’s findings and limitations in mind, it should be recognized that screening 
for adult depression in primary care is only beneficial in combination with adequate practices 
being in place to enhance the diagnosis, treatment, and management of care. Screening for 
depression alone does not translate to improved patient outcomes and quality of care (Picardi et 
al., 2016). Collaborative care to include support from behavioral health specialists in 
combination with screening has been associated with improved recognition of depression, patient 
adherence to treatment, treatment adequacy, and patient outcomes in primary care settings (Jiao, 
Rosen, Bellanger, Belkin, & Muennig, 2017). In order to enhance the results of this project, a 
collaborative care approach should be utilized to monitor the severity of depression, to provide 
adequate follow-up, and to ensure psychiatric referral for patients who are not improving or 
responding to treatment (Jiao et al., 2017).  
Time constraints related to screening for depression and positive screening results proved 
to be a major barrier for the clinical staff. The two-step screening approach with PHQ-2 and 
PHQ-9 was performed using paper screening tools, which had to eventually be scanned and 
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downloaded into the EHR, creating increased utilization of resources and time. Having the 
screening tools already built into the EHR and having the patients complete PHQ-2 and PHQ-9 
for every visit electronically prior to or upon check in may overcome the time and resource 
barriers and may help to sustain the improved screening rates. It may also be beneficial to have 
the MDD protocol integrated into the EHR to save time, improve provider adherence to 
evidence-based guidelines, and ensure adequate diagnosis, treatment, referral, and follow-up.  
The MDD protocol should continue to be used as a guide to improve provider adherence 
to evidence-based guidelines and to enhance care and outcomes for adults with depression. PCPs 
should continue to employ the measurement-based approach using PHQ-9 as a management tool 
for depression, and routinely for follow-up visits, to monitor the severity and treatment outcomes 
and to help guide and modify treatment plans. Treatment response, remission, and recurrence 
rates should be measured regularly to successfully evaluate the impact that the interventions have 
on improving quality of care for adults with depression and to continually sustain and/or improve 
outcomes. Further exploration should be conducted to determine the specific reasons for non-
referral of depressed patients by PCPs to behavioral health specialists to improve the referral 
process and better align the clinic with ICSI guidelines.  
Implications for Practice  
Development and adherence to evidence-based protocols by PCPs for the screening, 
diagnosis, treatment, and management of adult depression in primary care can help push patients 
toward remission and improve patient outcomes and overall quality of care. Implementation of a 
suicide protocol can be useful in improving the recognition, assessment, and minimization of 
suicide risk in depressed patients in the primary care setting. Findings of this evidence-based 
quality improvement project support screening for depression in adults in the primary care 
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setting using PHQ-2 and PHQ-9 can improve the recognition of depression in patients, which 
may have otherwise gone undetected and untreated. Overall, screening for depression in adults in 
combination with having adequate systems of care in place to ensure proper diagnosis, treatment, 
follow-up, and management of depression is a cornerstone in improving quality of care and 
patient outcomes.  
With depression being underdetected, underdiagnosed, and undertreated in primary care, 
Advanced Practice Registered Nurses can be instrumental in the improvement of the recognition, 
diagnosis, and treatment of MDD. The Advanced Practice Registered Nurse is in a key position 
to provide oversight and to successfully implement the necessary changes to improve provider 
adherence to evidence-based guidelines for the screening, diagnosis, treatment, and management 
of adult depression in primary care. Implementation of a similar MDD protocol with evidence-
based guidelines and adequate screening for depression has the potential to significantly impact 
not only the patient, but also their loved ones and society as a whole.  
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Appendix A 
PHQ-2 in English 
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Appendix B 
PHQ-2 in Spanish 
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Appendix C 
PHQ-9 in English 
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Appendix D 
PHQ-9 in Spanish  
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Appendix E 
PHQ-2 Scoring and Interpretation  
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Appendix F 
PHQ-9 Scoring and Interpretation  
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Appendix G 
Letter of Support  
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Appendix H 
MDD Provider Handbook & Education Plan 
MDD Provider Handbook Materials: Copy of the ICSI Guidelines for each PCP, copies of the 
PHQ-2 and PHQ-9 in English and Spanish with instructions on how to score and interpret, copy 
of DSM-5 diagnostic criteria for MDD, copy of clinic’s MDD Provider Treatment 
Recommendation Table: Translating PHQ-9 Scores into Practice, copy of MDD in Primary Care, 
copy of clinic’s MDD Suicide Protocol for the assessment, minimization, and management of 
suicide risk, and copy of Data Collection Form 
Education:  
1) Screening Procedure using the PHQ-2 and PHQ-9 
a. Instructions on how to fill out forms  
b. Instructions on how to score forms 
c. Instructions on how to interpret scores  
2) DSM-5 Diagnostic Criteria for MDD  
3) MDD in Primary Care: Common presentations, risk factors, how & when to screen for 
depression using the PHQ-2 and PHQ-9, how to use the PHQ-9 to monitor treatment 
response, and when to refer to behavioral health specialist  
4) MDD Provider Treatment Recommendation Table: How to translate PHQ-9 depression 
scores into practice based on DSM-5 criteria and ICSI guidelines  
5) MDD Suicide Protocol to assess, minimize, and manage suicide risk 
a. How to screen for suicide ideation using Question 9 of PHQ-9 
b. How to assess suicide risk 
c. Suicide risk factors  
d. When to refer patient for inpatient psychiatric evaluation/treatment  
e. Texas Legislation regarding emergency detention (Texas Health and Safety Code 
611.004 & 574.034)  
f. When, how, and who to contact for emergency detention 
g. Local & national suicide prevention resources 
6) Duties and responsibilities for completion of Data Collection Form  
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Appendix I 
DSM-5 Diagnostic Criteria for MDD 
DSM-5 Diagnostic Criteria: Major Depressive Episode 
To qualify for a diagnosis of major depressive episode, the patient must meet criteria A 
through E:  
A. Five or more of the following symptoms have been present and documented during the 
same two-week period and represent a change from previous functioning; at least one of the 
symptoms is either (1) depressed mood or (2) loss of interest or pleasure.  
 
Note: Do not include symptoms that are clearly attributable to another medical condition.  
1) Depressed mood most of the day, nearly every day, as indicated by either 
subjective report (e.g., feels sad, empty, hopeless) or observation made by others 
(e.g., appears tearful)  
 
2) Markedly diminished interest or pleasure in all, or almost all, activities most of 
the day, nearly every day (as indicated by either subjective account or 
observation)  
 
3) Significant weight loss when not dieting or weight gain (e.g., a change of more 
than 5% of body weight in a month), or decrease or increase in appetite nearly 
every day  
 
4) Insomnia or hypersomnia nearly every day  
 
5) Psychomotor agitation or retardation nearly every day (observable by others, not 
merely subjective feelings of restlessness or being slowed down)  
 
6) Fatigue or loss of energy nearly every day  
 
7) Feelings of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self-reproach or guilt about being sick)  
 
8) Diminished ability to think or concentrate, or indecisiveness, nearly every day 
(either by subjective account or as observed by others)  
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9) Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific plan for committing 
suicide  
 
B. The symptoms do not meet criteria for a mixed episode.  
 
C. The episode is not attributable to the physiological effects of a substance or to another 
medical condition. Note: Criteria A-C represent a major depressive episode. Note: Responses 
to a significant loss (e.g., bereavement, financial ruin, losses from a natural disaster, a serious 
medical illness or disability) may include feelings of intense sadness, rumination about the 
loss, insomnia, poor appetite and weight loss noted in Criterion A, which may resemble a 
depressive episode. Although such symptoms may be understandable or considered 
appropriate to the loss, the presence of a major depressive episode in addition to the normal 
response to a significant loss should also be carefully considered. This decision inevitably 
requires the exercise of clinical judgment based on the individual's history of and the cultural 
norms for the expression of distress in the context of loss.  
 
D. The occurrence of the major depressive episode is not better explained by schizoaffective 
disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified 
and unspecified schizophrenia spectrum and other psychotic disorders.  
 
E. There has never been a manic episode or a hypomanic episode. Note: This exclusion does not 
apply if all of the manic-like or hypomanic-like episodes are substance induced or are 
attributable to the physiological effects of another medical condition. Severity is based on the 
number of criterion, the severity of those symptoms and the degree of functional disability.  
 
 Mild, single episode ICD-10 F32.0, recurrent episode ICD-10 F33.0: Few, if any 
symptoms in excess of those required to make the diagnosis are present, the 
intensity of the symptoms is distressing but manageable, and the symptoms result 
in minor impairment in social or occupational functioning.  
 
 Moderate, single episode ICD-10 F32.1, recurrent episode ICD-10 F33.1: The 
number of symptoms, intensity of symptoms, and/or functional impairment are 
between those specified for "mild" and "severe."  
 
 Severe, single episode ICD-10 F32.2, recurrent episode ICD-10 F33.2: The 
number of symptoms is substantially in excess of that required to make the 
diagnosis, the intensity of symptoms is seriously distressing and unmanageable, 
and the symptoms markedly interfere with social and occupational functioning. 
Further specifications include:  
 
(Institute for Clinical Systems Improvement, 2016) 
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 In partial remission, single episode ICD-10 F32.4, recurrent episode ICD-10 
F33.41: Symptoms of the immediately previously major depressive episode are 
present, but full criteria are not met, or there is a period lasting less than two 
months without any significant symptoms of a major depressive episode 
following the end of such an episode.  
 
 In full remission, single episode, recurrent episode ICD-10 F33.42: During the 
past two months, no significant signs or symptoms of the disturbance were 
present. 
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Appendix J 
 
MDD in Primary Care  
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Appendix K 
MDD Provider Algorithm  
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Appendix L 
MDD Provider Treatment Recommendation Table: Translating PHQ-9 Scores into Practice  
 
 
 
 
 
   
M D D  P R O V ID E R  T R E A T M E N T  R E C O M M E N D A T IO N  T A B L E :  T R A N S L A T IN G  P H Q -9  
S C O R E S  IN T O  P R A C T IC E  
*At every level of severity, add education, physical activity, and behavioral activation to standard 
treatment r ecommendations. 
 
Sev er it y  
P HQ-9 
Score s  
Possi ble D iag noses  Treatm ent Reco mme ndat ions  
Undef ined  
Initial 
Score:  5-9  
Does not meet 
criter ia for major 
depressiv e d isorder  
Consider for 
persi ste nt 
depressiv e d isorder  
Stay  in touch: 
a) I f no impro vement after o ne or more 
months, co nsider treat ing or referra l to 
beha viora l hea lth.  
 
b) If sympto ms deter iorate, start treat ment or 
make a refer ral.  
 Follow-up 
Score:  5-9  
Parti al remiss ion  Continue stepped therap ies approach.  
Per DSM -5: 
Few, if a ny, s ympto ms in excess of those req uired to make the 
diagnos is are prese nt, the intensity of the s ympto ms is d istress ing 
but managea ble, a nd the s ympto ms res ult in min or impairment in 
soci al or occ upat ional functioning.  
10-14  
Mild major 
depressi on  
 
Combin ed ps ychotherap y and 
pharm acotherap y treat ment.  
Whe n unable to do co mbin ed therap y due to 
pati ent prefere nces, a vailabili ty and 
affordabil ity of the t reat ments, st art w ith 
psychotherap y.  
Init ially  co nsider week ly contacts to e nsure 
adequ ate e ngage ment, the n at least monthly.  
 
Per DSM -5: 
The number of s ympto ms, inte nsity of s ympto ms, a nd/or  
fun ctio nal im pairm en t are betw een  tho s e s p ecified for “m ild” an d 
“s evere.”  
15-19  
Moderate m ajor 
depressi on  
Combin ed ps ychotherap y and 
pharm acotherap y treat ment.  
Whe n unable to do co mbin ed therap y due to 
pati ent prefere nces, a vailabili ty and 
affordabil ity of the treat ments, start w ith 
psychotherap y.  
Init ially  co nsider week ly contacts to e nsure 
adequ ate e ngage ment, the n at least e very 2-4 
weeks.  
Per DSM -5: 
The number of s ympto ms is s ubsta ntially  in excess of that 
requi red to make the d iag nosis, the intensity of the s ympto ms is 
seri ously distress ing a nd unmanagea ble, a nd the s ympto ms 
marked ly interfere w ith soc ial and occ upat ional funct ioning.  
≥ 2 0  
Severe major 
depressi on  
Combin ed ps ychotherap y and 
pharm acotherap y treat ment.  
Whe n unable to do co mbin ed therap y due to 
pati ent prefere nces, a vailabili ty and 
affordabil ity of the t reat ments, st art w ith 
pharm acotherap y.  
Week ly co ntacts until less se vere.  
Meets DSM -5 cr iter ia for pers iste nt depress ive d isorder   Pure d ysth ymia  
Consider start ing w ith med icat ion.  
Consider stepped care , wh ich includes 
augmenting medicat ions a nd add ing 
p s ycho therapy for patien ts  w ho  do n ’t 
impro ve.  
Meets DSM -5 cr iter ia for pers iste nt depress ive d isorder   
Chro nic major 
depressi on  
Combin ed ps ychotherap y and 
pharm acotherap y treat ment.  
(Institute for Clinical Systems Improvement, 2016) 
IMPROVING PROVIDER ADHERENCE TO MDD GUIDELINES 67 
Appendix M 
 
MDD Suicide Protocol  
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Appendix N 
Data Collection Form  
 
 
